valdecoxib

Known as: 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide, 4-(5-methyl-3-phenyl-isoxazol-4-yl)benzenesulfonamide, valdecoxib [Chemical/Ingredient] 
A sulfonamide derivative and non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic activities. Valdecoxib… (More)
National Institutes of Health

Related topics

Related topics

10 relations

Narrower (1)

Bextra

Broader (3)

Cyclooxygenase 2 InhibitorsIsoxazolesSulfonamides
Degenerative polyarthritisDrug AllergyDysmenorrheaPregnancy
(More)

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2007
Review
2007
Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association.
Clinical trial data have prompted questions about the degree to which patients and their physicians should consider an increased… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Safety and efficacy of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib after noncardiac surgery.
BACKGROUND Valdecoxib and its intravenous prodrug parecoxib are reported to increase thromboembolic risk after coronary artery… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2006
2006
Fast Dissolving Valdecoxib Tablets Containing Solid Dispersion of Valdecoxib
Valdecoxib is a new non-steroidal antiinflammatory drug, mainly used for osteoarthritis, rheumatoid arthritis, and dysmenorrhea… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.
BACKGROUND Valdecoxib and its intravenous prodrug parecoxib are used to treat postoperative pain but may involve risk after… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2005
2005
Parecoxib, valdecoxib, and cardiovascular risk.
Selective inhibitors of cyclooxygenase (COX)-2 1 depress prostacyclin (PGI2) but not COX-1–derived thromboxane A2. The effects of… (More)
Is this relevant?
2005
2005
Valdecoxib-associated acute generalized exanthematous pustulosis.
AGEP (acute generalized exanthematous pustulosis) is a relatively rare exfoliative skin syndrome consisting of generalized… (More)
Is this relevant?
2005
2005
Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.
The discovery of a second isoform of cyclooxygenase (COX) led to the search for compounds that could selectively inhibit COX-2 in… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Stability study of amorphous valdecoxib.
Formulation of poorly water-soluble drugs in the most stable dosage form for oral delivery perhaps presents the greatest… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery.
OBJECTIVE Inhibition of cyclooxygenase 2 provides analgesia in ambulatory patients. We prospectively evaluated the safety and… (More)
Is this relevant?
2002
2002
Valdecoxib does not impair platelet function.
The platelet effects of a supratherapeutic dose of the new cyclooxygenase (COX)-2 specific inhibitor, valdecoxib (40 mg twice a… (More)
Is this relevant?